osimertinib,blu-945
blueprint medicines,astrazeneca
['blu-945', 'osimertinib', 'blu-945 ', 'nsclc', 'sclc']
in #asco23's rapid abstract session at 11:42am cdt, presents findings from a phase 1/2 study of blu-945 monotherapy &amp; combo with osimertinibin in patients with #nsclc: #crukfunded
We're here to support our broad cancer research community of 4,000 scientists and clinicians. For general Cancer Research UK news & fundraising follow @CR_UK